Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
Author:
Publisher
Ferrata Storti Foundation (Haematologica)
Subject
Hematology
Reference16 articles.
1. Bradstock KF, Papageorgiou ES, Janossy G. Detection of Leukaemic lymphoblasts in CSF by immunofluorescence for terminal transferase. Lancet. 1980; 1(8178):1144.
2. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?. Blood. 2014; 124(23):3345-3355.
3. Pui CH, Pei D, Coustan-Smith E. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic Leukaemia: a prospective study. Lancet Oncol. 2015; 16(4):465-474.
4. Vora A, Goulden N, Wade R. Treatment reduction for children and young adults with low-risk acute lymphoblastic Leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14(3):199-209.
5. Short NJ, Ravandi F.. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. Haematologica. 2019; 104(8):1532-1541.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3